Simple Summary Immune checkpoint inhibitors (ICIs) are novel cancer therapeutics that
address the immune system to attack malignancies. While this therapy has significantly …

Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that
target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell …

Simple Summary With nonspecific activation of the immune system, immune checkpoint
inhibitors (ICIs) can lead to off-target immune-related adverse events (irAEs) to every organ …

Background: This present study investigated the incidence rates of cardiotoxicity among
cancer patients treated with immune checkpoint inhibitors (ICIs) plus other anticancer drugs …

Background Treatment with immune checkpoint inhibitors (ICIs) has been associated with
an increased rate of cardiac events. There are limited data on the risk factors that predict …

Immune checkpoint molecules are physiological regulators of the adaptive immune
response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting …

Background Immune checkpoint inhibitors (ICI) are a novel class of anti‐cancer therapy
becoming increasingly associated with fatal cardiovascular toxicities (CVTs). The aim is to …

Background Immune checkpoint inhibitors (ICI) are associated with immune-mediated
adverse effects, potentially involving any organ. ICI has also been associated with an …

Recent years have brought major advancements in the use of immune therapy and
specifically immune checkpoint inhibitors (ICIs) in cancer patients, with expanding …

Objective Recently, several researchers have reported the incidence of cardiac-related
toxicities occurring with nivolumab (Opdivo) and pembrolizumab (Keytruda). There is still a …